Search

everythinglearnresearchcommunity

for

Search:↓

Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.

Topical tofacitinib is effective and safe for treating alopecia areata.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

Hypothyroidism is often linked to the hair loss condition telogen effluvium.

The updated SALT II tool offers a more precise way to measure scalp hair loss.

Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.

The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.

The AI system HairComb accurately scores hair loss severity, matching dermatologist assessments.

Hydroxychloroquine may help treat alopecia areata in children.

Injecting platelet-rich plasma or applying it with a laser or microneedling can treat hair loss effectively. The laser and microneedling methods cause less pain.

Male gender and family history predict alopecia areata recurrence.

Alopecia areata significantly lowers the quality of life, especially in emotional and mental health aspects.

Alopecia areata involves immune system imbalances that may lead to depression and anxiety.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

People with alopecia areata often have lower vitamin D levels, which may be linked to the condition's severity.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

Combining TRA and latanoprost is most effective for treating localized alopecia areata.

Ayurvedic treatment significantly reduced hair loss and improved hair quality in a 30-year-old male.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

People with alopecia areata often have lower vitamin D levels and more inflammation, suggesting vitamin D might be involved in the condition.

Bimatoprost was found to be safer and more effective than mometasone furoate for treating scalp hair loss.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.

Carboxytherapy may help increase hair growth in alopecia patients but requires ongoing treatment.

Dupilumab for skin problems might reactivate hair loss in some patients.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

The PRP-like cosmetic with biomimetic peptides is potentially effective and safe for treating alopecia areata.